TITLE

Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients

AUTHOR(S)
Halpern, Alfredo; Pepe, Renata B.; Monegaglia, Ana Paola; Beyruti, Mônica; de Melo, Maria Edna; Mancini, Marcio C.
PUB. DATE
January 2010
SOURCE
Journal of Obesity;2010, Vol. 2010, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective. To assess the efficacy and tolerability of the association sibutramine (10-20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were assessed every 2 weeks during a period of 3 and 6 months. Results. After 3 months, the mean weight loss was 10.5 kg (-9.8% of the initial weight, n = 263), and after 6 months, the mean weight loss was 13.9 kg (-12.8% of the initial weight, n = 97). The tolerability of such association was quite acceptable and coherent with the action mechanism of each component. Conclusions. The association of orlistat and sibutramine is quite efficient and it seems to promote a higher rate of weight loss than that reported in clinical studies performed with each drug separately.
ACCESSION #
57622426

 

Related Articles

  • Pharmacotherapy of Obesity: An Update. Schurgin, Sunita; Siegel, Richard D. // Nutrition in Clinical Care;Jan-Apr2003, Vol. 6 Issue 1, p27 

    There has been an epidemic of obesity in the last decade, In spite of the rising numbers of people who are overweight and obese, medical treatment of obesity is currently where medical treatment of hypertension was in the 1950s with only two Food and Drug Administration-approved medications for...

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...

  • Orlistat, sibutramine, and rimonabant reduce weight in overweight and obese persons. Kanaya, Alka M. // ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p24 

    The article focuses on 30 randomized controlled trials (RCTs) investigating the long-term efficacy of antiobesity drugs (AODs) for reducing weight and improving health status in overweight or obese persons. Trials found out that orlistat, sibutramine and rimonabant reduces weight and improve...

  • NICE gives go-ahead for rimonabant.  // Pulse;7/9/2008, Vol. 68 Issue 24, p18 

    The article reports on the approval of the use of rimonabant in obese patients who cannot take orlistat and sibutramine by the National Institute for Health and Clinical Excellence (NICE) in Great Britain. The institute has advised that there must be careful consideration of current or previous...

  • Anti-obesity Agents: A Focused Review on the Structural Classification of Therapeutic Entities. Sangmi Oh; Koon Soon Kim; Young Sun Chung; Minho Shong; Seung Bum Park // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p466 

    In addition to its enormous impacts on an individual's quality of life, obesity is a daunting health problem in the world today and the increasing rate of obesity is now causing a severe burden on health care systems. Fortunately, the normalization or reduction of increased body fat reverses the...

  • New drug policy in childhood obesity. Molnár, D.; Molnár, D // International Journal of Obesity;Sep2005 Supplement 2, Vol. 29, pS62 

    Objective: To update physicians, especially paediatricians, in the rapidly developing field of pharmacotherapy of childhood and adolescent obesity.Methods: The paper reviews current and investigational antiobesity drugs.Results: At present, there are only...

  • A pharmacologic approach to obesity. Lucas, Charles P.; Segal, Karen R.; Hauptman, Jonathan // Contemporary OB/GYN;Jun2000, Vol. 45 Issue 6, p18 

    Evaluates the effectiveness of orlistat for the treatment of obesity. Gender-specific effects of obesity; Effect of orlistat on weight loss; Side effects of orlistat. INSET: Fighting obesity.

  • The Straight Dope On Weight-Loss Drugs. Fentress, Debbie; Agnew, Bruce // Diabetes Forecast;Apr2002, Vol. 55 Issue 4, p51 

    Provides information on weight-loss drugs, Xenical, Meridia and phentermine. Overview of studies on the drugs; Side effects of weight loss drugs; Contents of the drugs. INSET: Beware herbal remedies.

  • Antidote. Siegel, Marc // Medical Marketing & Media;Apr2006, Vol. 41 Issue 4, p14 

    The article examines some weight loss drugs in the United States. Xenical or Orlistat are drugs that hinder fat absorption into the gastrointestinal tract. An appetite suppressant, Meridia prevents the reabsorption of serotonin, a hormone in the brain that is released when a patient is full from...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics